Rotavirus (Rotarix/RotaTeq)
Rotavirus Vaccine (Rotarix / RotaTeq)
Platform: Oral live attenuated
Oral vaccine that protects against rotavirus, the leading cause of severe diarrheal disease in infants and young children.
PubMed References
Immunology Sections
Curated section analysis in progress
Structured immunology sections — mechanism, immune response, molecular signatures, correlates of protection, and more — are being prepared by the Precision Vaccines Program team. In the meantime, verified references and live literature from PubMed, Semantic Scholar, and Wikipedia are available below.
Verified References
Wikipedia Overview
Full article ↗A rotavirus vaccine is a vaccine used to protect against rotavirus infections, which are the leading cause of severe diarrhea among young children. These vaccines prevent 15–34% of severe diarrhea in the developing world and 37–96% of the risk of death among young children due to severe diarrhea. Immunizing babies decreases rates of rotavirus disease among older people and those who have not been immunized.
PubMed Literature
Search PubMed ↗No PubMed results retrieved.
Semantic Scholar
Search S2 ↗Jingjiao Li, Yu Liu, Xinghuan Ma et al. · 2026
1 citationsA lipid nanoparticle (LNP) platform that codelivers messenger RNA and the retinoic acid receptor agonist Am80 is introduced, enabling antigen-specific mucosal immune responses in the gut via parenteral intramuscular vaccination and suggesting that Am80-LNP may offer a versatile mRNA vaccine platform against gastrointestinal viruses.
Benjamin Lee, Md Abdul Kader, E. R. Colgate et al. · 2021
11 citationsDeveloping controlled human infection models for group A rotaviruses, especially in prospective studies with larger sample sizes, may be a promising tool to assess rotavirus vaccine efficacy and CoPs.
Theresa K. Resch, Yuhuan Wang, Sung-Sil Moon et al. · 2018
44 citationsThis study is the first to show that parenterally administered IRV can induce mucosal immunity in the gut, in addition to strong serum antibody response, and is a promising candidate vaccine in achieving global immunization against rotavirus.
Jun Wang, Songkang Qin, Kuanhao Li et al. · 2025
6 citationsThis review summarizes the RV colonization of the intestine and stimulation of intestinal immunity, as well as recent advancements in RV reverse genetics, and focuses on their application in the rational design of a multivalent mucosal vaccine vector targeting enteric pathogens considering the advantages and challenges of RV as a vector.
Sufen Li, Xuechao Tang, Jinzhu Zhou et al. · 2024
5 citationsThe NSP4* as a synergistical antigen exerted limited effects on the PoRV NAbs elevation, but conferred strong VP4*-specific mucosal and cellular efficacy, which lays the foundation for the development of a more effective porcine rotavirus subunit vaccine.